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Abstract
Background. The GO-MORE study was an open-label, multinational, prospective study that investigated 
the efficacy and safety of adding golimumab to synthetic disease-modifying antirheumatic drugs (sDMARDs) 
in patients with active rheumatoid arthritis (RA).
Objectives. The aim of this study was to assess the efficacy and safety of golimumab add-on therapy 
in the Polish subpopulation of the GO-MORE study.
Material and methods. Patients were administered 50 mg subcutaneous doses of golimumab once 
a month for 6 months, while continuing therapy with sDMARDs and/or glucocorticoids (GCS). The primary 
clinical endpoint was the proportion of patients with moderate or good European League Against Rheuma-
tism (EULAR) response based on the 28-joint disease activity score (DAS28) erythrocyte sedimentation rate 
(ESR) after 6 months.
Results. The Polish subpopulation (129 patients) was similar to the overall study population (3,280 patients) 
with regard to age, sex, mean baseline DAS28, inflammatory markers, average methotrexate dose, and GCS 
use; however, they had a longer disease duration (median: 6.04 vs 4.9 years) and more Polish patients (85.9% 
vs 78.7%) had high disease activity (DAS28–ESR ≥3.2). At 6 months, 84.5% of Polish patients showed good 
or moderate EULAR response, 26.4% had low disease activity and 17.1% were in clinical remission, compared 
with 82.9%, 37.4% and 23.9%, respectively, in the overall study population. Golimumab safety profile was 
consistent with previous studies and comparable to the overall study population.
Conclusions. The addition of golimumab to sDMARD therapy in Polish RA patients showed good or moderate 
EULAR DAS28–ESR response in 84.5% of patients, mirroring the overall study population.
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Introduction
According to the current recommendations for the man-
agement of rheumatoid arthritis (RA), the main treat-
ment goal is to attain remission of the disease symptoms, 
or alternatively to achieve low disease activity in patients 
who fail to attain remission with the available treatment 
methods.1–3 The recommendations specify time peri-
ods in which this treatment goal should be achieved; i.e., 
improvement should be achieved within 3 months and 
the treatment goal (remission or  low disease activity) 
should be met within 6 months.1,2 To achieve this goal, 
synthetic disease-modifying antirheumatic drugs (sD-
MARDs) are recommended in the 1st phase of RA treat-
ment. The first-line conventional sDMARD is methotrex-
ate (MTX). If MTX is not tolerated or contraindicated, 
then leflunomide, sulfasalazine or hydroxychloroquine, 
alone or  in  combination with glucocorticoids (GCS), 
are recommended. In case of inefficacy or adverse reac-
tions, other conventional sDMARDs or biologic agents 
are recommended. The recommended first-line biologics 
include tumor necrosis factor alpha (TNF-α) inhibitors, 
abatacept, tocilizumab, and, in  certain conditions, 
rituximab.2
Table 1. Baseline clinical and demographic characteristics of the GO-MORE study patients, including the Polish population9
Characteristics Overall study population Polish patient group
Number of patients in the study 3280 129
Age [years]
mean (SD) 52.3 (12.8) 49.7 (11.06)
median (min, max) 53.0 (18, 88) 52.0 (18, 78)
Females, n (%) 2716 (86.8) 111 (86)
Race, n (%)
Caucasian 2283 (69.6) 129 (100)
other 997 (30.4) 0
BMI [kg/m2], median (min, max) 26.2 (14.0, 54.5) 24.96 (16.7, 42.6)
Disease duration [years]
mean (SD) 7.6 (7.9) 8.78 (8.69)
median (min, max) 4.9 (0.01, 56.6) 6.04 (0.12, 44.6)
DAS28–ESR
n 3270 129
mean (SD) 5.97 (1.1) 5.96 (0.94)
high disease activity (>5.1), n (%) 2572 (78.7) 110 (86)
DAS28–CRP mean (SD) 5.41 (1) 5.34 (0.9)
CRP [mg/L] mean (SD) 14.48 (20.38) 13.46 (18.62)
ESR [mm/h] mean (SD) 34.9 (24.64) 32.8 (18.98)
Anti-CCP
n 3225 129
positive (≥20 U/mL), n (%) 2318 (71.9) 102 (79)
Rheumatoid factor
n 3234 129
positive (≥15 U/mL), n (%) 2344 (72.5) 127 (98)
HAQ-DI mean (SD) 1.44 (0.67) 1.51 (0.57)
sDMARD
n 3270 129
methotrexate monotherapy, n (%) 1681 (51.4) 87 (67)
methotrexate + leflunomide, n (%) 216 (6.6) 1 (1)
methotrexate + sulfasalazine, n (%) 150 (4.6) 8 (6)
methotrexate + hydroxychloroquine, chloroquine, n (%) 433 (13.2) 10 (8)
methotrexate + hydroxychloroquine, chloroquine + 
sulfasalazine, n (%)
106 (3.2) 1 (1)
leflunomide monotherapy, n (%) 303 (9.3) 8 (6)
Glucocorticoids
n 3280 129




1, n (%) 1129 (34.4) 28 (22)
2, n (%) 1176 (35.9) 48 (37)
≥3, n (%) 974 (29.7) 53 (41)
anti-CCP – anti-cyclic citrullinated peptide antibody; BMI – body mass index; CRP – C-reactive protein; DAS28 – 28-joint disease activity score;  
DMARD – disease-modifying antirheumatic drugs; ESR – erythrocyte sedimentation rate; GCS – glucocorticoids; HAQ-DI – health assessment  
questionnaire disability index.
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A new generation of TNF-α inhibitor is golimumab, 
an anti-TNF-α monoclonal antibody that is administered 
subcutaneously (SC) once a month. Golimumab has been 
extensively evaluated in placebo-controlled RA clinical 
studies; it  has shown efficacy in  MTX-naïve patients, 
in patients with inadequate response to MTX, in patients 
previously treated with at  least one TNF-α inhibitor. 
Furthermore, golimumab can inhibit radiographic pro-
gression in the joints of MTX-naïve patients and of those 
with inadequate MTX response.4–8 GO-MORE study was 
the first to evaluate the efficacy and safety of golimumab 
as an add-on therapy to different sDMARDs and to low 
doses (<15 mg/week) of MTX.9
The GO-MORE study evaluated golimumab as an add-
on therapy (alone or in combination) to MTX, leflunomide, 
sulfasalazine, hydroxychloroquine, and chloroquine. This 
mimics the real-life clinical situation, when golimumab 
is typically administered in conjunction with different 
DMARDs.
The GO-MORE study included 129 Caucasian Polish 
patients from 13 centers across Poland. As the response 
to and safety of synthetic and biological DMARDs in-
cluding golimumab may be genetically determined, and 
could be affected by different standards of  treatment 
in various countries, the results of the GO-MORE study 
may vary across populations.10,11 Therefore, we set out 
to investigate whether the efficacy of golimumab in a Pol-
ish subpopulation differed from the international study 
population, which combined ethnic groups and standards 
of treatment.
Objectives
The objective of the paper was to evaluate the efficacy 
and safety of golimumab as an add-on therapy to standard 
DMARDs in the Polish patient subgroup (129 patients) 
from the 1st part of the GO-MORE study, and to compare 
the efficacy results with worldwide study population.
Material and methods
This was a post-hoc analysis of the GO-MORE study 
(P06129; NCT00975130) which evaluated the  efficacy 
and safety of golimumab in RA patients under conditions 
closely resembling routine clinical practice.9 The GO-
MORE study was an open-label, prospective, multicenter 
clinical trial that was conducted in 40 countries across 
Europe, Asia, North America, South America, and Africa, 
and involved 475 centers. It was approved by Bioethics 
Committees and conducted according to Good Clinical 
Practice and Declaration of Helsinki.
The study enrolled 3,280 patients with RA, aged over 
18 years, diagnosed according to the revised 1987 crite-
ria of the American College of Rheumatology.12 Disease 
activity was evaluated using the 28-joint disease activ-
ity score (DAS28). The study patients had active form 
of the disease (DAS28–ESR ≥ 3.2) despite treatment with 
1 or  more of  the  following sDMARDs at  stable doses 
for at least 1 month: MTX, sulfasalazine, hydroxychloro-
quine, chloroquine, chloroquine phosphate, leflunomide, 
gold salts, azathioprine, or cyclosporine. The exclusion 
criterion was prior use of biologics and any contraindica-
tions for TNF-α inhibitor use.
The study consisted of 2 parts. In part 1, the patients re-
ceived 50 mg of SC golimumab, once a month for 6 months. 
Throughout the study the patients continued taking their 
regular doses of sDMARDs and/or GCS. Part 2 of the study 
included patients who did not attain remission after 
6 months, but achieved good or moderate response ac-
cording to the EULAR criteria.13 The patients were ran-
domly assigned (1:1) to one of 2 treatment groups receiving 
for the following 6 months 50 mg of SC golimumab once 
a month or combination regimen of SC and IV golimumab. 
Patients who did not participate in the study part 2 could 
continue golimumab therapy until week 48 as an exten-
sion of part 1.
The  primary endpoint of  part 1 was the  percentage 
of patients who achieved good or moderate EULAR re-
sponse (defined as DAS28–ESR improvement of >1.2 from 
a baseline score or an improvement of 0.6–1.2 in the case 
of a baseline score of ≤5.1). The key secondary endpoints 
included percentage of remissions and low disease ac-
tivity according to DAS28–ESR, DAS28 calculated with 
C-reactive protein (CRP), simplified disease activity in-
dex (SDAI) and percentage of  patients who developed 
minimal or no functional impairment (health assessment 
questionnaire disability index, HAQ-DI, ≤0.5). The es-
sential efficacy evaluation criterion for both therapeutic 
regimens in part 2 was the percentage of patients who at-
tained DAS28–ESR remission at the start of month 11 and 
at the end of month 12. Part 2 of the study included 505 
patients with only a small number of Polish subjects (13), 
and therefore, this paper presents an analysis of results 
obtained with the Polish population participating in part 
1 of the study.
Results
Baseline characteristics of the Polish 
patient group
The overall results of the GO-MORE study have been 
previously reported.9
The Polish GO-MORE clinical trial included 129 pa-
tients (Table 1). The majority (83%) of the patients enrolled 
in the study used MTX, and most took high doses of MTX 
(≥15 mg/week). A significantly lower proportion of patients 
(33%) took a sDMARD other than MTX, and only 16% 
of these patients received a sDMARD in combination with 
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MTX. The second most frequently used sDMARD was 
leflunomide (6% of patients in the Polish subpopulation 
and 9.3% of patients in the overall study population), and 
the remaining patients received a combination treatment, 
mostly MTX with chloroquine or hydroxychloroquine 
(13%). Tritherapy (MTX, hydroxychloroquine/chloroquine 
and sulfasalazine) was administered to only 1% of patients 
in the Polish subpopulation compared to 3.2% of patients 
in  the overall population. The baseline characteristics 
of the Polish group of patients were similar to the overall 
study population in terms of age, sex, the mean baseline 
DAS28, HAQ-DI value, number of painful and swollen 
joints, laboratory inflammation markers, MTX dose, and 
percentage of patients treated with GCS (Table 1). Com-
pared to the overall study population, the Polish patient 
population was characterized by a longer disease duration 
(median: 6.04 vs 4.9 years), a higher percentage of patients 
with high disease activity according to DAS28–ESR (86% 
vs 78.7% of patients), and a higher number of previous fail-
ures with at least 3 sDMARDs (41% vs 29.7% of patients).
Efficacy of golimumab
After 6 months of golimumab treatment, 85% (109/129) 
of the patients in the Polish subpopulation achieved good 
or moderate EULAR response, which was the primary 
part 1 endpoint. Low disease activity (DAS28–ESR < 3.2) 
after 6 months of treatment was achieved by 26% (34/129) 
and remission (DAS28–ESR < 2.6) was achieved by 17% 
(22/129) of patients. The percentage of patients who met 
the criterion of good or moderate EULAR response after 
6 months (85%) was similar to the overall study population 
mean of 82.1%. The percentage of low disease activity and 
remission achieved after 6 months in the Polish patient 
population was lower than in the overall study population, 
i.e., 26% vs 37.4% and 17% vs 23.9%, respectively (Table 2).
The percentage of Polish patients who met the criteria 
of good or moderate EULAR response increased over time 
(i.e., 58% at the beginning of month 2, 78% at the beginning 
of month 4, and 85% at the end of month 6), which was 
similar to the overall population data (i.e., 64.9%, 76.9% 
and 82.1%, respectively). The percentage of Polish patients 
who attained remission over time also increased (i.e., to 3%, 
12% and 17%, respectively), but these percentages were 
lower than in the overall population (i.e., 7.7%, 16.1% and 
17.1%, respectively) (Table 2). There was a mean decrease 
in DAS28–ESR within 6 months of golimumab therapy 
from 5.96 (baseline) to 2.19 ( ±1.19).
The mean baseline SDAI score decreased from 35.16 
at  baseline to  21.96 (  ±12.23) at  the  end of  treatment 
month 6. A total of 45% of patients (58/129) achieved low 
disease activity (SDAI < 11) and 10% of patients (13/129) 
achieved remission (SDAI < 3.3) after 6 months. Simi-
lar to the results seen with DAS28–ESR, the percentage 
of Polish patients achieving low disease activity according 
to SDAI increased over time, reaching 16%, 32% and 45% 
in months 2, 4 and 6, respectively. The percentage of Polish 
patients achieving remission according to SDAI also in-
creased over time to 2%, 8% and 10% in months 2, 4 and 6, 
respectively. In the Polish group, these percentages based 
Table 2. Percentage of patients who achieved good or moderate response, low disease activity or remission, according to DAS28–ESR (EULAR criteria) 
at subsequent measurement points. Results obtained in the Polish cohort (n = 129) and in the overall study population (n = 3280) are presented 
for comparison9
DAS28–ESR (EULAR)













Patients who achieved good or moderate 
response to the treatment (%)
64.9 58 76.9 78 82.1 85
Patients who achieved low disease activity
(DAS28–ESR < 3.2) (%)
16.6 9 28.1 21 37.4 26
Patients who achieved remission
(DAS28–ESR < 2.6) (%)
7.7 3 16.1 12 24 17









No or minimal functional impairment(HAQ-DI ≤ 0.5), n (%) 8 (6) 18 (14) 26 (20) 25 (19)
Minimal (acceptable) disease symptoms(PASS), n (%) 14 (11) 59 (46) 74 (57) 94 (73)
HAQ-DI – health assessment questionnaire disability index; PASS – patient acceptable symptom state.
Table 4. The effect of golimumab on Polish patients’ quality of life as determined by the EQ-5D (n = 129)
Before treatment (baseline) Beginning of month 2 Beginning of month 4 End of month 6
EQ-5D (mean ±SD) 0.44 ±0.28 0.15 ±0.22 0.19 ±0.26 0.22 ±0.26
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on SDAI were lower than the percentages of low disease 
activity and remission determined by the DAS28–ESR 
in the overall study population.
Subgroup analysis of efficacy 
of golimumab
A subgroup analysis of the Polish patients showed no sig-
nificant differences in the percentages of patients who 
achieved good or moderate EULAR response at the end 
of month 6 due to the dose of MTX, the use of DMARDs 
other than MTX, the number of previously failed DMARDs, 
and the use or non-use of GCS. 
Effect of golimumab on quality of life
The effect of golimumab treatment on the patients’ phys-
ical function was measured in all patients using the HAQ-
DI score. Prior to  the  treatment, the  patients’ general 
physical function measured by HAQ-DI was 1.51 ±0.568, 
and disease activity evaluation by the patient using visual 
analogue scale (VAS) 0–100 mm was 63.56 ±17.357. Golim-
umab treatment significantly improved the patients’ func-
tional condition and more patients reported symptoms 
that were acceptable and did not disturb their everyday life 
(Table 3). In addition to the functional condition improve-
ment, the patients treated with golimumab also reported 
an improved quality of  life, as measured by the EQ-5D 
questionnaire (Table 4). The percentage of Polish patients 
without a disability or with minimal impairment of func-
tion (HAQ-DI ≤ 0 5) increased from 6% at baseline to 14%, 
20% and 19% at the beginning of month 2, 4 and the end 
of month 6, respectively. In addition, the percentage of Pol-
ish patients exhibiting minimal (acceptable) disease symp-
toms (patient acceptable symptom state, PASS) increased 
from 11% at baseline to 46%, 57% and 73% at the beginning 
of month 2, 4 and the end of month 6, respectively. There-
fore, treatment with golimumab significantly improved 
patients’ physical function as assessed by HAQ-DI, and 
significantly improved health-related quality of life.
Safety and tolerability of golimumab
Golimumab safety was evaluated in  all patients 
in the study in relation to adverse events observed dur-
ing treatment (treatment emergent adverse event, TEAE). 
The percentage of Polish patients with at least 1 TEAE was 
45% in part 1 of the study, and 15% of patients had a drug-
related TEAE (Tables 5, 6). Abnormal laboratory results 
were observed in 3% of the patients, with the most common 
being elevated serum aminotransferase, elevated potassium, 
decreased thyroid stimulating hormone, or decreased fi-
brinogen. No deaths occurred during part 1 of the study 
or within 30 days after the last dose. Therefore, golimumab 
was well-tolerated in the Polish cohort, and the safety profile 
was consistent with previous studies on the drug.
Discussion
In this analysis of the GO-MORE study in the Polish 
subpopulation (129 patients), we found that SC treatment 
with 50 mg of golimumab once a month for 6 months, 
in combination with different sDMARDs, resulted in good 
or moderate EULAR response in the majority of patients 
(85%). By  the  2nd month of  treatment, more than half 
of the Polish patients (58%) had already achieved good 
or moderate EULAR response, and after 4 months, this 
proportion had increased to 78% of the patients. The data 
is similar to that observed in the overall GO-MORE study 
population.9 On the other hand, remission rates in the Pol-
ish subpopulation improved more gradually; 3%, 12% and 
17% of patients had achieved remission at the beginning 
Table 5. Adverse events in the Polish patient subpopulation (n = 129) 
during golimumab treatment
Categories of adverse events n (%)
All adverse events 59 (45)
Drug-related adverse events 20 (15)
Serious adverse events 4 (3)
Adverse events leading to early withdrawal 3 (2)
Deaths 0
Adverse injection site reactions 0
Clinically significant abnormal laboratory results 5 (3)
Table 6. Adverse events in the Polish patient subpopulation (n = 129) 
during 6 months of golimumab treatment according to various organ 
system manifestations
Organ system manifestations Adverse events, n (%)
Infections 31 (24)
Musculoskeletal system 8 (6)
Gastrointestinal system 7 (5)
Respiratory system 6 (5)
Skin 6 (5)
General symptoms 5 (4)
Abnormal laboratory results 5 (3)
Metabolic disorders 4 (3)
Arterial hypertension 4 (3)
Hematologic disorders 3 (2)
Neoplasms: benign, malignant and unspecified 3 (2)
Nervous system 3 (2)
Dysrhythmias 2 (2)
Serious adverse 
events (SAE), n (%)
Discopathy 1 (1)
Skin melanoma 1 (1)
Dysrhythmias 1 (1)
Endometrial hyperplasia 1 (1)
S. Jeka, et al. Efficacy and safety of golimumab498
of month 2, 4 and the end of month 6, respectively. There-
fore, although the clinical response with a combined go-
limumab therapy is achieved relatively early, it may take 
more time to achieve the main RA treatment goals, such 
as remission or low disease activity.
The remission rate (17%) observed in the Polish sub-
population using golimumab is similar to that observed 
previously using other anti-TNF-α drugs. For example, 
Hyrich et al. found that the remission rates (measured 
by DAS28) for 4000 RA patients, monitored after the 1st 
year, and subsequently from 2001 to 2008, after treatment 
with different anti-TNFα drugs (i.e., etanercept, infliximab 
and adalimumab) ranged from 8% to 19.4%.10 On the other 
hand, in the CORRONA study, remission rates measured 
by DAS28 were slightly higher; after 6 months of adalim-
umab (874 patients), etanercept (640 patients) or inflix-
imab (728 patients) therapy, remission rates were 25.2%, 
28.4% and 28.2% of patients, respectively.14 However, this 
difference in remission rates may have occurred as the pa-
tients in the CORRONA study had lower mean baseline 
disease activity (DAS28 = 4.4) compared to  the Polish 
subpopulation of the GO-MORE study (DAS28 = 5.96). 
Moreover, the remission rate was lower after 6 months 
of treatment in the Polish subpopulation (17%) compared 
to the overall GO-MORE study population (23.9%). This 
difference may be due to the fact that the Polish patients 
had a longer disease duration compared to the overall study 
population (6.04 vs 4.9 years) and, therefore, they were 
most likely to be in a more advanced stage of the disease. 
Indeed, there were more Polish patients with high disease 
activity (i.e., DAS28–ESR > 5.1) compared to the overall 
study population (86% vs 78.7%). There was also a larger 
proportion of Polish patients with the presence of rheu-
matoid factor and/or  anti-cyclic citrullinated peptide 
compared to the overall study population (99% vs 72.5% 
and 79% vs 71.9%, respectively), which usually indicates 
poorer outcomes in RA patients. In addition, the Polish 
subpopulation had a higher proportion of patients who 
had been previously unsuccessfully treated with at least 
3 sDMARDs compared to the overall study population 
(41% vs 29.7%). Finally, there are differences in  access 
to drugs and in treatment standards between Poland and 
other countries examined in the GO-MORE study, which 
could explain the minor differences in remission rates 
to golimumab treatment in the Polish subpopulation com-
pared to the entire study population.
We also found that the proportion of Polish patients 
who achieved remission or had low disease activity was 
lower when measured using SDAI compared to DAS28–
ESR. Using SDAI, only 10% of patients achieved remis-
sion and 45% of  patients showed low disease activity 
after 6 months of treatment. This discrepancy between 
the DAS28 and SDAI results is probably due to the fact 
that SDAI includes the assessment of the patient’s general 
condition by the physician. The physician may evaluate 
the patient’s symptoms more rigorously than the patient 
themselves, who have become accustomed to the chronic 
ailments. Moreover, as the mean DAS28, CRP and ESR 
values were comparable between the Polish subpopulation 
and the overall study population, the lower remission and 
low disease activity rates (according to both DAS28–ESR 
and SDAI) in Polish patients compared to the overall study 
population should be interpreted with caution. Indeed, this 
may simply be due to the fact that the Polish subpopulation 
had a larger proportion of patients with higher baseline 
disease activity (DAS28–ESR > 5.1), as mentioned above.
A larger group of patients received MTX in the Polish 
subpopulation (83%) compared to the overall study popu-
lation (79.0%); 67% of the Polish subpopulation and 51.4% 
in the overall study population were in MTX monotherapy. 
In addition, a larger proportion of Polish patients received 
MTX at high doses exceeding 15 mg/week. A significantly 
lower proportion of patients (33%) took a sDMARD other 
than MTX and only 16% of these patients received a sD-
MARD in combination with MTX. 
The  Polish subpopulation of  the  GO-MORE study 
showed a significant improvement in terms of physical 
function and quality of life, and golimumab was effective 
in patients who had shown insufficient response to previ-
ous therapies with 1 or more sDMARDs. The adverse events 
profile in the Polish subpopulation was similar to the over-
all study population and to that described in previous stud-
ies using golimumab, and was also similar to that observed 
using other anti-TNF-α drugs.9,11,15,16 The most commonly 
observed adverse events were infections, and serious events 
were reported in only 3% of the Polish patients. In addition, 
no deaths or injection site reactions occurred in the Polish 
subpopulation.
The basic limitation of this analysis of the Polish sub-
population of the GO-MORE study was the small group 
of participants (129 patients), which makes it difficult 
to conduct a statistical analysis of golimumab efficacy 
among individual subgroups. The  subgroup analysis 
showed no significant differences in the percentages of pa-
tients who achieved good or moderate EULAR response 
at the end of month 6 depending on MTX dose, use of sD-
MARDs other than MTX, number of failed sDMARDs, 
and use or non-use of GCS. Despite this, due to the small 
size of the Polish patient group, and consequently very 
small subgroups, the data should be interpreted with cau-
tion. Nevertheless, taking into account that the overall 
study population showed no efficacy differences among 
the  abovementioned subgroups, the  results obtained 
in the Polish patients seem to be reliable.9 Another po-
tential limitation of part 1 of the GO-MORE study may be 
its open-label character, which can have an inherent bias. 
However, results of the observational phase of the study 
may be most representative for the RA patient population, 
which is common in rheumatological practice. 
In  conclusion, the  results of  the  GO-MORE study 
in the Polish population show the efficacy and safety of go-
limumab as an add-on treatment to different sDMARDs, 
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with or without GCS therapy, in patients with RA in whom 
previous DMARD therapies had failed, demonstrating 
good or moderate EULAR DAS28–ESR response in a large 
proportion of patients (85%). The onset of action was rapid, 
with good tolerability, and a safety profile consistent with 
the data described for golimumab in other clinical trials 
and in the Summary of Product Characteristics.
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